Table 1.
Baseline characteristics of 190 participants according to ICP diagnosis, 2019–2020.
| Variables | NC (n = 95) | ICP (n = 95) | P value |
|---|---|---|---|
| Age, median (IRQ), years | 29, (27; 32) | 30, (28; 34) | ns |
| TP, median (IRQ), (g/L) | 64.5, (62.4; 66.7) | 62.9, (60.1; 64.5) | < 0.001 |
| ALB, median (IRQ), (g/L) | 35.7, (34.6; 37.4) | 34.9, (33.1; 36.6) | 0.003 |
| ALT, median (IRQ), U/L | 12, (10; 17) | 17, (11; 32) | < 0.001 |
| TB, median (IRQ), μmol/L | 6.0, (4.8; 7.9) | 7, (5.2; 9.3) | 0.006 |
| DB, median (IRQ), μmol/L | 2.4, (1.9; 3.1) | 2.7, (2.1; 4.1) | 0.001 |
| IB, median (IRQ), μmol/L | 3.5, (2.8; 4.4) | 4.1, (2.9; 5.5) | 0.033 |
| TBA, median (IRQ), μmol/L | 2, (1; 3) | 13, (11; 19) | < 0.001 |
| CR, median (IRQ), μmol/L | 44.2, (39.6; 48.03) | 50.4, (44.1; 56.1) | < 0.001 |
| UREA, median (IRQ), mmol/L | 2.45, (2.08; 2.87) | 2.70, (2.19;3.16) | 0.017 |
| URIC, median (IRQ), μmol/L | 235, (210.8; 269.5) | 232, (200; 309) | ns |
| TG, median (IRQ), mmol/L | 2.50, (1.99; 3.19) | 2.35, (1.84; 3.28) | ns |
| TCH, median (IRQ), mmol/L | 6.27, (5.58; 6.90) | 6.08, (5.37; 6.63) | ns |
| HDL, median (IRQ), mmol/L | 1.73, (1.57; 1.93) | 1.79, (1.51; 2.02) | ns |
| GLU, median (IRQ), mmol/L | 4.37, (4.19;4.52) | 4.34, (4.15;4.57) | ns |